Assisted reproduction is included in the medical insurance reimbursement policy! According to Zhejiang Daily, residents who participate in Hangzhou's commercial supplementary medical insurance "Xihu Yilianbao" from 2023 will receive reimbursements of up to 3,000 yuan for assisted reproduction in 2023.
Since this year, various regions have actively explored and promoted the inclusion of assisted reproduction in medical insurance, and relevant support policies have been gradually improved. Driven by the huge market demand prospects, many listed companies are also stepping up their layout.
Assisted reproduction is included in the medical insurance policy.
According to Hangzhou City policy, embryo culture and embryo culture are accepted during treatment at provincial and municipal tertiary medical institutions with specific assisted reproduction qualifications within Hangzhou City. For the cost of the two transplant treatments, "Xihu Yilianbao" will provide a certain limit of subsidies, of which the reimbursement limit for embryo culture expenses is 0.15 million yuan/year, and the reimbursement limit for embryo transplantation expenses is 0.15 million yuan/year, within the annual limit. Actual reimbursement can be made according to the project, and the portion exceeding the limit will be borne by the insured personally.
In terms of news, at the end of October this year, the National Health Commission held a symposium on population work. The meeting proposed that it is necessary to speed up the establishment of a fertility support policy system and coordinate the introduction of more supporting measures; it is necessary to improve working mechanisms such as the target management responsibility system, strengthen overall planning, policy coordination and work implementation, and promote long-term balanced development of the population.
Prior to this, the Zhejiang Provincial Health Commission has publicly stated that it will actively promote the inclusion of assisted reproductive technology projects in medical insurance.
Some organizations said that the current cost of assisted reproduction is relatively high. After assisted reproduction projects are included in medical insurance, more people will have the opportunity to undergo assisted reproduction treatment, which will help promote the healthy development of the assisted reproduction industry in the long run.
The policy support system is increasingly improving
Industry insiders said that in recent years, the country has successively launched the "two-child policy" and the "three-child policy" to further meet the people's reproductive health needs.
In August this year, 17 departments including the National Health Commission and the National Development and Reform Commission issued the "Guidance on Further Improving and Implementing Active Maternity Support Measures", which for the first time clearly stated that it would guide local governments to comprehensively consider medical insurance (including maternity insurance). ) Fund affordability, relevant technical standardization and other factors, gradually include appropriate labor analgesia and assisted reproductive technology projects into the scope of fund payment according to procedures.
Prior to this, medical insurance management departments in many places have stated that they will gradually explore the inclusion of assisted reproductive technology projects in medical insurance. Among them, the Hunan Provincial Medical Insurance Bureau stated in May this year that it would gradually explore the inclusion of medical insurance-affordable therapeutic assisted reproductive technology into the scope of medical insurance payment according to procedures. The Suzhou Municipal Medical Insurance Bureau also stated that assisted reproductive technology, which is in high clinical demand, will be included in the scope of medical insurance payment in a timely manner.
In addition, as early as February this year, the Beijing Medical Insurance Bureau also issued a notice that it planned to include 16 assisted reproductive technology projects such as intrauterine artificial insemination and embryo transfer, which are common in outpatient treatment, into medical insurance.
The market has broad prospects
Industry insiders said that although the subject of assisted reproductive technology in my country started late, it has developed very rapidly in recent years. However, the current penetration rate of assisted reproductive services in my country is still low, and there is broad room for market development in the future.
According to reports, the current assisted reproductive industry chain can be roughly divided into upstream assisted reproductive drugs, testing reagents, and equipment suppliers, midstream "Internet + assisted reproductive services" online platform, and downstream assisted reproduction. Medical service provider. Attracted by the huge market prospects, listed companies such as Jinxin Fertility, International Medicine, Dajia Weikang and Hanshang Group have stepped up their deployment in recent years.
A recent research report released by Industrial Securities pointed out that with the promotion of population policies, the prosperity of the assisted reproductive industry continues to rise. In addition, the increasingly stringent supervision of the assisted reproductive industry will also promote the standardized development of the entire industry.
Recently, the assisted reproduction sector has once again experienced a rise. As of November 25, the assisted reproduction index was at 4410.53.